Valuation
- Market cap
- 130,794,000
- Revenue TTM
- $11,160,000
- Net income TTM
- $-148,130,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1,327.33%
- Debt to equity
- 0.00
Trading
- Volume
- 866,500
- Avg volume
- 1,088,876
- Day's range
- $1.22 – $1.24
- Shares out
- 107,208,000
- Stochastic %K
- 3%
- Beta
- 2.31
- Analysts
- Strong Sell
- Price target
- $11.86
Company profile
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy...
Show more
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 510 982 6030
- Website
- https://cariboubio.com
- Address
- 2929 7th Street, Suite 105, Berkeley, United States
Latest news
No headlines yet.
